Bio & Pharma
GI Cell wins approval for human cell management from Korean regulator
The company aims to produce cells to be used in cell therapy development, clinical trials
By Dec 27, 2022 (Gmt+09:00)
1
Min read
Most Read
Deutsche Bank's Korea IB head quits after country head resigns
Hanwha buys S’pore Dyna-Mac’s stake for $73.8 mn from Keppel
Macquarie Korea Asset Management confirms two nominees
Meritz leaves door open for an M&A, to stay shareholder friendly
Korea's Taeyoung to sell local hotel to speed up debt workout
GI Cell, a South Korean developer of immune cell therapy products, received a human cell and others management license from South Korean regulatory, said GI Innovation, GI Cell's affiliate, on Tuesday.
The permission allows GI Cell to produce and supply human cells, which are raw materials for biopharmaceuticals.
To acquire approval from the Ministry of Food and Drug Safety, GI Cell secured an independent workplace with advanced biopharmaceutical manufacturing and quality management facilities, the company said.
They will be used to facilitate the production and supply of cells to be used in cell therapy development and clinical trials in the future.
"Our goal is to pass the regulator's suitability test for a trial plan of T.O.P. NK (tumor targeting, optimally primed NK), an allogeneic NK cell therapy, and win approval for cell processing facilities in the first half of next year," said Kim Hyung-min, head of GI Cell's GMP department.
Write to Jeong-Min Nam at peux@hankyung.com
More to Read
-
Bio & PharmaS. Korea's GI Cell, Japanese partner to study cell therapy for blood cancer
Dec 14, 2022 (Gmt+09:00)
1 Min read -
Celltrion to co-develop pill-type autoimmune disease drug with UK startup
Aug 20, 2020 (Gmt+09:00)
1 Min read
Comment 0
LOG IN